Bevacizumab

Genentech, Inc.
460 Point San Bruno Blvd.
South San Francisco, CA 94080-4990
(650) 225-1000

TEST MATERIAL SAFETY INFORMATION

IDENTITY

Product Name: rhuMAb VEGF (recombinant humanized monoclonal antibody against vascular endothelial cell growth factor)
Biological Activity: Binds to endogenous VEGF
Chemical Family: Protein, antibody

TYPICAL COMPOSITION

Components:
25 mg/mL rhuMAb VEGF
51 mM sodium phosphate
pH 6.2

Threshold limit value/
permissible exposure limit: None

PHYSICAL PROPERTIES

pH: 6.2
Appearance and odor: slightly opalescent, colorless liquid, odorless
Vapor pressure: NA
Solubility: NA

FIRE AND EXPLOSION HAZARD DATA

Unusual fire and explosion hazards: None
Special fire fighting procedure: Not Applicable
Flash point (test method): Not Applicable
Lower explosion limit: Not Applicable
Dot hazard classification: None
Extinguishing media: Not Applicable
Auto ignition temperature (°C): Not Applicable
Upper explosion limit: Not Applicable
Shipping name: rhuMAb VEGF

REACTIVITY PROPERTIES

Stability: Stable

Storage Conditions: There are no special conditions to avoid for safety purposes. Store at 2 to 8°C for protection of rhuMAb VEGF activity. DO NOT SHAKE. Filter protein prior to use.

Conditions to avoid: There are no special conditions to avoid for safety purposes. Heat will degrade the protein. Hazardous decomposition products: None

PHYSIOLOGIC EFFECTS

Symptoms and health risk of overexposure

Preclinical toxicology studies were performed to support the clinical use of rhuMAb VEGF administered as multiple weekly intravenous (IV) injections. These studies included 4-week, 13-week, and 26-week toxicology studies and a safety/pharmacokinetic study of rhuMAb VEGF in combination with cisplatin/paclitaxel in cynomolgus monkeys. The effects seen after treatment with rhuMAb VEGF were most likely due to the pharmacologic inhibition of the action of VEGF which included physeal dysplasia in animals with open growth plates and decreased ovarian and uterine weights in female animals. There were no overt signs of acute toxicity. For handling in an occupational setting, no adverse health effects are expected to be produced following accidental eye or skin contact, or upon inhalation or ingestion of this product. This product is not readily absorbed through the skin.

Emergency and first aid procedures:
In case of contact, immediately flush eyes or skin with copious amounts of water. If swallowed, wash out mouth with water. If an irritation or allergic reaction does occur following contact, see a physician.

Carcinogen or potential carcinogen and source:

National Toxicology Program:	*Yes [ ]*	*No [ ]*	*Not tested [X]*
OSHA	*Yes [ ]*	*No [ ]*	*Not tested [X]*
I.A.R.C. Monographs	*Yes [ ]*	*No [ ]*	*Not tested [X]*

SPECIAL PROTECTION INFORMATION

No special ventilation or protective equipment are required. Wear standard laboratory or manufacturing protective garments.

LEAK PROCEDURES AND DISPOSAL METHODS

Spills: Wear protective garments as appropriate for cleaning up a non-hazardous material.

Waste disposal methods: Dispose of material in accordance with local standards and practices.

SPECIAL PRECAUTIONS AND LABELS

In accordance with FDA regulations the following cautionary label is appropriate:

CAUTION: Contains a new drug for investigational use only in laboratory research animals or for test *in vitro*, not for use in humans.

The above information is offered in good faith and with the belief that it is accurate. As of the date of issuance, we are providing all information relevant to the foreseeable handling of the material. However, in the event of an adverse incident associated with this product, this Test Material Information Sheet is not, and is not intended to be, a substitute for consultation with appropriately trained personnel.

Date of Issue: August 17, 2001